Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study

BACKGROUND: Evaluate efficacy and safety of paliperidone palmitate 6-monthly (PP6M) for patients with schizophrenia in the Asian subgroup of a global, multicenter, noninferiority phase-3 study (NCT03345342). METHODS: Patients received paliperidone palmitate 1-monthly (PP1M, 100/150 mg eq.) or palipe...

Descripción completa

Detalles Bibliográficos
Autores principales: Richarz, Ute, Han, John, Bai, Ya-Mei, Yu-Hai Chen, Eric, Chung, Young Chul, Jhanwar, Venu Gopal, Kim, Sung-Wan, Sulaiman, Ahmad Hatim, Knight, Karl, Gopal, Srihari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5000
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470698/
https://www.ncbi.nlm.nih.gov/pubmed/37653768
http://dx.doi.org/10.1097/MD.0000000000034623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470698/
https://www.ncbi.nlm.nih.gov/pubmed/37653768
http://dx.doi.org/10.1097/MD.0000000000034623

Ejemplares similares